Concor

Bisoprolol fumarate

HTN, CHD (angina pectoris), stable chronic heart failure w/ reduced systolic left ventricular function in addition to ACE inhibitors & diuretics & optionally cardiac glycosides.

HTN or angina pectoris 5 mg once daily, may be increased to 10 mg once daily. Stable chronic heart failure 1.25 mg once daily for 1 wk, if well-tolerated increase to 2.5 mg once daily for a further wk, if well-tolerated increase to 3.75 mg once daily for a further wk, if well-tolerated increase to 5 mg once daily for the following 4 wk, if well-tolerated increase to 7.5 mg once daily for the following 4 wk, if well-tolerated increase to 10 mg once daily for maintenance therapy. Max: 10 mg once daily. HTN or angina pectoris in patients w/ severe renal (CrCl <20 mL/min) or liver insufficiency Max: 10 mg once daily.

May be taken with or without food: Swallow whole, do not chew/crush.

Hypersensitivity. Acute heart failure or during episodes of heart failure decompensation requiring IV inotropic therapy; cardiogenic shock, 2nd- or 3rd-degree AV block (w/o pacemaker); sick sinus syndrome; SA block; symptomatic bradycardia or hypotension; severe bronchial asthma; late stages of peripheral arterial occlusive disease & Raynaud's syndrome; untreated phaeochromocytoma, metabolic acidosis.

Avoid abrupt w/drawal in patients w/ ischaemic heart disease. Patients w/ HTN or angina pectoris & accompanying heart failure. DM w/ large fluctuations in blood glucose values, hypoglycemia, strict fasting, ongoing desensitisation therapy, 1st-degree AV block, Prinzmetal's angina, peripheral arterial occlusive disease; IDDM, severe renal or hepatic impairment, restrictive cardiomyopathy, congenital heart disease, haemodynamically significant organic valvular disease, MI w/in 3 mth; bronchial asthma or other COPD; existing or history of psoriasis, Do not administer in patients w/ phaeochromocytoma until after α-receptor blockade. May mask thyrotoxicosis symptoms. Reduced incidence of arrhythmias & myocardial ischemia in patients undergoing general anaesth during induction & intubation & post-op period. May affect ability to drive or operate machinery. Pregnancy. Breastfeeding is not recommended during administration. Not recommended for childn.

Bradycardia (in patients w/ chronic heart failure). Worsening of pre-existing heart failure (in patients w/ chronic heart failure); dizziness, headache; GI complaints (eg, nausea, vomiting, diarrhoea, constipation); cold or numb feeling in the extremities, hypotension especially in patients w/ heart failure; asthenia (in patients w/ chronic heart failure), fatigue.

May potentiate AV conduction time & increase negative inotropic effect w/ class I anti-arrhythmics. May lead to profound hypotension & AV block w/ verapamil IV. May further decrease central sympathetic tonus leading to reduction of heart rate & cardiac output, & to vasodilatation w/ centrally-acting antihypertensives (eg, clonidine, methyldopa, moxonidine, rilmenidine); risk of rebound HTN when abruptly w/drawn. May increase risk of hypotension w/ Ca antagonists (dihydropyridine type eg, felodipine & amlodipine) & other drugs w/ BP lowering potential (eg, TCAs, barbiturates, phenothiazines). May potentiate effect on AV conduction time w/ class-III antiarrythmics (eg, amiodarone). Risk of bradycardia w/ parasympathomimetic drugs. May have additive systemic effects w/ topical β-blockers. Intensified blood sugar lowering effect of insulin & oral antidiabetics; may mask hypoglycemia symptoms. Attenuate reflex tachycardia & increase risk of hypotension w/ anaesth agents. Increased AV conduction time w/ digitalis glycosides. May reduce hypotensive effects by NSAIDs. May have mutual reduced effects w/ β-sympathomimetics. Increased BP & exacerbated intermittent claudication w/ α- & β-adrenoreceptors. Increased risk of bradycardia w/ mefloquine. Enhanced hypotensive effects & risk of hypertensive crisis w/ MAOIs.

Beta-Blockers

C07AB07 - bisoprolol ; Belongs to the class of selective beta-blocking agents. Used in the treatment of cardiovascular diseases.

POM